COVID-19 vaccine from Anhui earns conditional approval
By Wang Xiaoyu |
chinadaily.com.cn |
Updated: 2022-03-02 17:20
Share
Share - WeChat
China has given conditional approval for a recombinant protein subunit COVID-19 vaccine developed by domestic company Anhui Zhifei Longcom Biopharmaceutical, the National Medical Products Administration said on Wednesday.
The vaccine uses purified pieces of the virus' protein to trigger an immune response. It is the first vaccine based on this technology to be approved by the top drug regulator.
In total, five COVID-19 vaccines have been approved for public use in China so far.
- Xi, Tokayev attend ceremony of exchanging cooperation documents
- Zhuhai checkpoints leading to Macao, Hong Kong register 100 million trips
- What the Shenzhou XX astronauts are doing after over 50 days in space
- Beijing-Tianjin-Hebei logistics index hit 52.17% in Q1 of 2025
- Science Talk: Is Red Sun threat rumor or reality?
- 6 remain missing after fireworks factory blast in Hunan, 1 dead
